SavedAdd your journal

Journals / Çocuk Dergisi / 2021 / Cilt: 21 - Sayı: 1

Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience

Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi

Yöntem YAMAN
Murat ELLİ
Kürşat ÖZDİLLİ
Leyla TELHAN
Nihan BAYRAM
Volkan HAZAR
Ebru TUĞRUL
Şifa ŞAHİN
Sema ANAK
Pages
7–12
Publication Date
2021-05-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Eight of them are still alive.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Nearly 20% of patients with Hodgkin Lymphoma (HL) who receive standard treatment will relapse or have a refractory disease.
📊
Key Findings & Data:Method: We retrospectively evaluated 18 pediatric patients with RR HL who underwent AHSCT between November 2014 and July 2019.
💡
Conclusion & Impact:Eight of them are still alive.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Hodgkin Lenfoma · Kök Hücre Nakli · brentuksimab

Abstract

Background: Nearly 20% of patients with Hodgkin Lymphoma (HL) who receive standard treatment will relapse or have a refractory disease. Standard treatment for the Relapsed/Refractory (RR) HL is salvage high dose chemotherapy followed by autologous stem cell transplantation (AuSCT). Management of RR HL after AuSCT with allogeneic stem cell transplantation (ASCT) is also considered as an important salvage therapy. Objective: To describe the outcome in pediatric patients with RR HL who underwent AuHSCT and ASCT in Medipol University hematopoietic stem cell transplantation center. Method: We retrospectively evaluated 18 pediatric patients with RR HL who underwent AHSCT between November 2014 and July 2019. The evaluation of ASCT after RR HL AuSCT is also done. Results: Sixteen patients are still alive. Eleven of them relapsed after AuHSCT. AllogeneicHSCT was performed on 10 patients who relapsed. Relapse was seen in three patients after AHSCT. Eight of them are still alive.

Özet

Giriş: Standart tedavi alan Hodgkin Lymphoma (HL) hastalarının yaklaşık %20’sinde hastalık dirençli seyredebilir veya tekrar edebilir. Tekrar eden/ dirençli HL’da standart tedavi yüksek doz kemoterapi ve takip eden otolog kök hücre naklidir (OKHN). Otolog KHN sonrası tekrar eden hastalarda ise allojeneik kök hücre nakli (AKHN) önemli bir kurtarma tedavisi olarak görülmektedir. Amaç: Medipol Üniversitesi Tıp Fakültesi çocuk kemik iliği nakil ünitesinde OKHN ve AKHN yapılan hastalarda sonuçları değerlendirmek. Yöntem: Tekrar eden/dirençli HL nedeniyle 2014 Kasım ile Temmuz 2019 tarihleri arasında merkezimizde OKHN yapılan 18 olgu retrospektif olarak değerlendirilmiştir. Otolog KHN sonrası hastalığı tekrar eden ve AKHN yapılan hastalarda ayrıca değerlendirilmiştir. Bulgular: Onaltı hasta halen hayattadır. Onbir hastada OKHN sonrası hastalık tekrar etmiştir. Relaps eden hastalardan 10’una AKHN yapılmıştır. Bu hastalardan üçünde tekrar görülmüş olup, sekizi nakil sonrası hayattadırlar.

🔖

Cite This Article

YAMAN, Y., ELLİ, M., ÖZDİLLİ, K., TELHAN, L., BAYRAM, N., HAZAR, V., TUĞRUL, E., ŞAHİN, Ş., ANAK, S. (2021). Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience. Çocuk Dergisi, Cilt: 21 - Sayı: 1, 7–12. https://ajindex.com/articles/246764

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Christine Mauz-Körholz, Monika L. Metzger, Kara M, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 20;33(27):2975-85
  2. Schellong G, Bramswig J, Ludwig R, et al: Combined treatment strategy in over 200 children with Hodgkin’s disease: Graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy—A report of the cooperative therapy study DAL-HD-82 [in German]. Klin Pädiatr 198:137-146, 1986 3. Weiner MA, Leventhal BG, Marcus R, et al: Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 9:1591-1598, 1991 4. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: Results of the Children’s Cancer Group phase III trial. J Clin Oncol 16:897-906, 1998 5. Schellong G, Potter R, Bramswig J, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90—The German-Austrian Pediatric Hodgkin’s Disease study group. J Clin Oncol 17:3736-3744, 1999 6. Donaldson SS, Link MP, Weinstein HJ, et al: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 25:332-337, 2007
  3. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. New England Journal of Medicine. 2011; 365(3):203–212
  4. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. New England Journal of Medicine. 2016; 374(25):2419–2429
  5. Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991; 77(10):2292–2298
  6. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma. Biology of Blood and Marrow Transplantation. 2006; 12(10):1065–1072
  7. Satish Shanbhag, and Richard Ambinder. Hodgkin Lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018 March; 68(2): 116–132
  8. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over convent